SRNE - Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline
Sorrento Therapeutics (NASDAQ: SRNE) has added another arrow to its COVID-19 quiver . The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for patients with acute respiratory distress syndrome associated with COVID-19.
The MSC treatment was derived from fat cells, but the cells have the ability to turn into other types of tissue. "The data suggests stem cells have the ability to reduce inflammation, reduce scar tissue formation, and to aid in clearing the lungs of fluid," Robert Harman, CEO of Personalized Stem Cells, noted in May.
The Food and Drug Administration (FDA) authorized the start of a 20-patient phase 1 clinical trial in July, but the study hasn't started recruiting patients, according to ClinicalTrials.gov. The main purpose of the early-stage study is twofold: Assess the safety of the treatment and measure its risk/benefit ratio.
For further details see:
Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline